ESCITALOPRAM TABLET

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

ESCITALOPRAM (ESCITALOPRAM OXALATE)

Disponible desde:

RANBAXY PHARMACEUTICALS CANADA INC.

Código ATC:

N06AB10

Designación común internacional (DCI):

ESCITALOPRAM

Dosis:

10MG

formulario farmacéutico:

TABLET

Composición:

ESCITALOPRAM (ESCITALOPRAM OXALATE) 10MG

Vía de administración:

ORAL

Unidades en paquete:

100/500

tipo de receta:

Prescription

Área terapéutica:

SELECTIVE-SEROTONIN REUPTAKE INHIBITORS

Resumen del producto:

Active ingredient group (AIG) number: 0150435002; AHFS:

Estado de Autorización:

APPROVED

Fecha de autorización:

2015-05-05

Ficha técnica

_ _
_Pr_
_ESCITALOPRAM (Escitalopram Tablets, Mfr. Std.) Product Monograph _
_Page 1 of 59_
PRODUCT MONOGRAPH
PR
ESCITALOPRAM
Escitalopram Tablets, Mfr. Std.
10 mg and 20 mg escitalopram (as escitalopram oxalate)
ANTIDEPRESSANT / ANTIOBSESSIONAL
Ranbaxy Pharmaceuticals Canada Inc.
DATE OF PREPARATION:
2680 Matheson Blvd. E., Suite 200
March 24, 2015
Mississauga, Ontario
L4W 0A5
SUBMISSION CONTROL NO: 181798
Trademark owned by Ranbaxy Laboratories Limited
_ _
_Pr_
_ESCITALOPRAM (Escitalopram Tablets, Mfr. Std.) Product Monograph _
_Page 2 of 59_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................12
DRUG INTERACTIONS
..................................................................................................26
DOSAGE AND ADMINISTRATION
..............................................................................32
OVERDOSAGE
................................................................................................................35
ACTION AND CLINICAL PHARMACOLOGY
............................................................36
STORAGE AND STABILITY
..........................................................................................38
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................38
PART II: SCIENTIFIC INFORMATION
...............................................................................39
PHARMACEUTICAL INFORMATION
..............................